**BOOK BEFORE AUGUST 23 TO SAVE UP TO $600!**

**November 18 - 20, 2019** | Boston, MA

# 3rd Annual AFDD

## Anti-Fibrotic Drug Development

# Translating Therapeutic Success Across Clinical Phases and Fibrotic Conditions

The roadmap to anti-fibrotic drug development advancements

## 37 expert speakers including:

**Matthew Breyer**
Distinguished Scientist
**Janssen**

**Lisa Hazelwood**
Principal Scientist Research, Liver Disease and Fibrosis
**AbbVie**

**Glenn Rosen**
SVP Preclinical Translational Sciences Small Molecules
**Coherus BioSciences**

**Tim Johnson**
Executive Director Non-Haemophilia Commercial Assessment
**UCB**

**Rosza Schlenker – Herceg**
Executive Director - Clinical Research, Medical Affairs & Respiratory
**Boehringer-Ingelheim**

**Weilin Xie**
Senior Principal Scientist Biotherapeutics Department
**Celgene**

**Partners:** monARC Bionetworks · TherapeutAix · XYLYX · Biomodels FAST. INNOVATIVE. PREDICTIVE.

**14** in-depth case studies

**11** hours networking

**42** expert speakers

**100+** like-minded peers

**Tel:** (+1) 617 455 4188 **Mail:** info@hansonwade.com www.afdd-summit.com

hansonwade

# Welcome to the 3rd Annual Anti-Fibrotic Drug Development Summit (AFDD) 2019

## The industry's definitive guide to turning fibrotic mechanisms into clinically effective therapeutics across disease areas

**Join** over 100 fellow drug developers to disseminate the latest findings, build a comprehensive network of like-minded peers who share the same challenges and search for drug repurposing opportunities.

**Hear** from pharma and biotech companies of all sizes, as well as clinicians and leading academics for a complete picture of the current challenges and opportunities.

**Find** commonalities across disease areas that can be applied back at the lab with presentations from specialists across all fibrotic conditions including **NASH**, **IPF**, **CKD**, **cardiovascular**, **gastro-intestinal**, **Scleroderma**, **rare disease** and **ocular fibrosis**.

**The next generation of anti-fibrotic treatments will be born at the 3rd AFDD Summit.**

## Hear what previous attendees have to say

"This conference looks at things from a different angle than others in the field, with the emphasis on industry developments and direction rather than academic research. It was nice to hear from companies developing technologies and solutions to aid research in fibrosis as well as those looking for partners. I enjoyed listening to how different companies tackled problems"

Tim Johnson, Director Fibrotic Remodeling, UCB

"Excellent panel of speakers, thought provoking discussions"

Lynn Williams, Group Leader, University of Oxford

# Five Unmissable Highlights

### Compelling Case Studies

**The AFDD Summit** provides a forum for leaders to share the newest advancements in drug development for fibrotic conditions

### Diverse Discussions

Our panels bring together multi-specialty, cross background professionals to discuss the biggest challenges faced by the industry and discover the solution together

### Academic Showcase

Look to the future with the latest discoveries from the most prestigious academic institutions

### Productive Networking

From constructive conversations over coffee to dexterous discussions over drinks, our varied networking program has something for everyone

### Hands-on Workshops

We believe in practical learning and nothing champions this better than our 3 hour workshops



Tel: (+1) 617 455 4188 Mail: info@hansonwade.com
www.afdd-summit.com

hansonwade

# An Unrivaled Speaker Line-Up

**Zoe Johnson**
Chief Scientific Officer
**iOnctura**

**Lisa Hazelwood**
Principal Scientist Liver Disease and Fibrosis Discovery
**Abbvie**

**John Atkinson**
Senior Research Scientist Tissue Remodelling
**UCB**

**Richard Stratton**
Consultant Physician and Honorary Senior Lecturer
**University College London**

**Glenn Rosen**
Senior Vice President Preclinical Translational Sciences Small Molecule
**Coherus Biosciences**

**Matthew Breyer**
Distinguished Scientist CVM
**Janssen**

**Tim Johnson**
Director Immunology Therapeutic Area
**UCB**

**Ravi Kumar**
Senior Vice President and Chief Scientific Officer
**Acceleron Pharma**

**Pieter Muntendam**
Chief Executive Officer and Founder
**G3 Pharmaceuticals**

**Aftab Taiyab**
Research Scientist
**McMaster University**

**Kirby von Kessler**
Associate Director Clinical Development
**Lung Biotechnology**

**Masha Poyurovsky**
Vice President Discover Biology
**Kadmon Corporation LLC**

**Alexey Lugovskoy**
Chief Development Officer
**Morphic Therapeutics**

**Sten R. Sörensen**
Chief Executive Officer
**Cereno Scientific**

**Shervin Assassi**
Professor of Medicine and Co-Director of the UTHealth Scleroderma Program
**University of Texas Health Science Center at Houston**

**Robert Lafyatis**
Adjunct Professor Medicine
**Boston University**

**Anie Philip**
Professor Department of Surgery
**Research Institute of the McGill University Health Center**

**Yaron Ilan**
Director Department of Medicine
**Hebrew University Hadassah Medical Center**

**Sydney Montesi**
Instructor in Medicine
**Harvard University**

**Ganesh Raghu**
Professor Medicine in the Division of Pulmonary and Critical Care Medicine
**University of Washington**

**Min Lu**
Morphic Therapeutics
**Head of Fibrosis**

**Rozsa Schlenker - Herceg**
Executive Director Clinical Research, Medical Affairs and Respiratory
**Boehringer-Ingelheim**

**Rick Keenan Ph.D.**
Chief Scientific Officer
**OptiKira**

**Weilin Xie**
Senior Principal Scientist
**Celgene Corporation**

**Eliezer Zomer Ph.D.**
Vice President Drug Discovery and Manufacturing
**Galectin Therapeutics**

**Lee Borthwick**
Fibrosis Biology Lecturer and Chief Operating Officer FibroFind
**Newcastle University**

**Jean-Francois Thibodeau**
Research Scientist
**Prometic Biosciences**

**Gilles Tremblay**
Director Preclinical Development
**Forbius**

**Scott Macdonnell**
Senior Staff Scientist
**Regeneron**

**Mehran Moghaddam**
Chief Executive Officer
**OROX Biosciences**

**Scott Turner**
Vice President Translational Sciences
**Pliant Therapeutics**

**Emily Offer**
Principal Scientist and Team Leader
**Redx Immunology**

**Komathi Stem**
Chief Executive Officer
**MonArc Bionetworks**

**Bertram Pitt**
Professor of Medicine Emeritus
**University of Michigan School of Medicine**

**Rana Herro**
Junior Faculty Instructor
**La Jolla Institute for Immunology**

**Resat Cinar**
Staff Scientist
**National Institute on Alcohol Abuse and Alcoholism**

**Robert Edwards**
Director and CVM Clinical Project Specialist
**Janssen**

**Moustapha El-Amine**
Director Global Search and Evaluate
**AstraZeneca**

**Gail Walkinshaw**
Vice President Research
**FibroGen**

**Darcey Black PhD**
Co-founder and Director, Translational
**TherapeutAix**

**Simon Cruwys PhD**
Co-founder and Director, Pharmacology
**TherapeutAix**

**Dr John O'Neill**
Chief Scientific Officer
**XYLYX Bio**

# Pre-Conference Workshops
# Monday November 18 2019

## Registration and Welcome Coffee — 8:30 – 9:00

## Workshop A — 9:00 – 12:00

### Biomarkers 101

- Novel biomarkers: how to create them and how to apply them
- Hands-on demonstration of biomarker application to preclinical and clinical models
- Medical imaging and blood tests: the pros and cons of the latest technology
- Translating *in vivo* and *in vitro* models to clinical trials through consistent biomarker application

**Workshop Leader**

**Sydney Montesi**
Instructor in Medicine
**Harvard University**

## Lunch Networking Break — 12:00 – 13:00

## Workshop B — 13:00 – 16:00

### How to cure multifactorial fibrotic diseases "Kill Two Birds With One Stone: MRI-1867, Hybrid Inhibitor of Peripheral Cannabinoid Receptor 1 (CB1R) & Inducible Nitric Oxide Synthase (iNOS), for the Treatments of NASH & Liver, Lung and Skin fibrosis"

- Outlining rationale for multi-target approach by polypharmacology to develop effective therapies in complex progressive diseases such as NASH and fibrotic diseases
- Identifying dual targeting of peripheral cannabinoid receptor 1 (CB1R) and inducible nitric oxide synthase (iNOS) as an effective therapeutic strategy in obesity, diabetes, AFLD, NAFLD, NASH, liver, lung and skin fibrosis
- Introducing the concept of third-generation cannabinoid receptor 1 (CB1R) antagonists for metabolic and fibrotic disorders
- Demonstrating preclinical efficacy of MRI-1867, an orally bioavailable small molecule antagonist of peripheral CB1R/iNOS, in fibrotic disorders: liver, lung and skin fibrosis

**Workshop Leader**

**Resat Cinar**
Staff Scientist
**National Institute on Alcohol Abuse and Alcoholism**

## Workshop C — 13:00 – 16:00

### Mechanistic workshop: Inhibitors

- Discover fibrotic inducers to create the perfect mechanistic antidote
- Decipher the biological elements lacking in a fibrotic patient but found in a healthy patient
- The creation of inhibiting treatments: from R&D to clinical trials

**Workshop Leaders**

**Richard Stratton**
Consultant Physician and Honorary Senior Lecturer
**University College London**

**Rana Herro**
Junior Faculty Instructor
**La Jolla Institute for Immunology**

## Networking Coffee to Stay or Go — 16:00 – 16:30

# Conference Day One
## Tuesday November 19 2019

**8.00** **Registration and Welcome Coffee**

**Alexey Lugovskoy**
Chief Development Officer
**Morphic Therapeutics**

**8.20** **Chair's Opening Remarks**

## Keynote Panel Sessions

**8.30** **Panel: One Vision for the Future of Fibrosis**

- Understand the commonalities between varying fibrotic conditions to better prevent and reduce inflammation
- Develop a systematic approach to target fibrosis across organs
- Share data to learn from previous failures and streamline the drug development process
- Decide whether treatments should be targeting fibrosis as a disease itself or as a response to the disease within that organ

**Moderator:**

**Ganesh Raghu**
Professor Medicine in the Division of Pulmonary and Critical Care Medicine
**University of Washington**

**Panellists:**

**Matthew Breyer**
Distinguished Scientist CVM
**Janssen**

**Alexey Lugovskoy**
Chief Development Officer
**Morphic Therapeutics**

**Lisa Hazelwood**
Principal Scientist Liver Disease and Fibrosis Discovery
**Abbvie**

**9.10** **Panel: The Trials and Tribulations of Animal Models**

- Decide whether animal models are necessary or whether they can be bypassed
- Weigh the relevancy of precision-cut organ slices against the longevity of animal models
- Consider testing multiple animal models for a smoother transition to clinical trial

**Moderator:**

**Alexey Lugovskoy**
Chief Development Officer
**Morphic Therapeutics**

**Panellists:**

**John Atkinson**
Senior Research Scientist Tissue Remodelling
**UCB**

**Lee Borthwick**
Fibrosis Biology Lecturer and Chief Operating Officer FibroFind
**Newcastle University**

**Masha Poyurovsky**
Vice President Discover Biology
**Kadmon Corporation LLC**

**Glenn Rosen**
Senior Vice President Preclinical Translational Sciences Small Molecule
**Coherus Biosciences**

**9.50** **Speed Networking**
Establish meaningful business connections at a rapid rate. Efficiency at its finest.

**10.50** **Morning Networking Break**

## Research and Discovery Sessions: Novel Targets, Molecules and Pathways

**Mehran Moghaddam**
Chief Executive Officer
**OROX Biosciences**

**11.20** **Case Study: Novel Two Pronged Target Approach**

- Develop unique molecules that attack two targets simultaneously to stop the progression of fibrosis across the body
- Ensure secondary targets are relevant and do not enhance toxicity of treatment

**Eliezer Zomer Ph.D.**
Vice President Drug Discovery and Manufacturing
**Galectin Therapeutics**

**11.40 Therapeutics for Chronic Fibrotic Diseases**
- The next generation of Galectin-3 inhibitors: from R&D through to phase III clinical trials
- Discovery of functional allosteric inhibitors

**Dr John O'Neill**
Chief Scientific Officer
**XYLYX Bio**

**12.00 Disease-Specific Extracellular Matrix Cell Culture Substrates to Improve Predictive in Vitro Models of Fibrosis**
- Introducing a standardized, fully humanized commercial 3D cell culture platform for fibrosis research
- Describing the extracellular matrix (ECM) composition of the substrates that recapitulates the human disease environment in vitro
- Discussing how this platform can reduce the dependence on animal models, and enable more relevant scientific results leading to improved drug discovery process

**Scott Turner**
Vice President Translational Sciences
**Pliant Therapeutics**

**12.15 Case Study: Therapeutic Integrin Inhibition**
- Selective integrin inhibitors block TGF-B activation in a cell and tissue specific manner for the treatment of NASH and IPF
- PK and PD evaluation of dual αvβ6/αvβ1 inhibitors in humans and primates

**Pieter Muntendam**
Chief Executive Officer and Founder
**G3 Pharmaceuticals**

**12.35 Case Study: Galectin-3 as a Potential Treatment Target**
- Identify patients with galectin-3 mediated fibrogenesis by plasma galectin-3 levels
- Using the galectin-3 carbohydrate recognition domain as an on-off switch for treatment
- The promise of galectin-3 inhibition in cardiac and other conditions

**Darcey Black PhD**
Co-founder and Director, Translational
**TherapeutAix**

**Simon Cruwys PhD**
Co-founder and Director, Pharmacology
**TherapeutAix**

**12.55 Building a platform of evidence that will lead to clinical and partnering success in fibrotic disease**
- A view of the future clinical landscape in fibrotic disease – exemplified by IPF and NASH, and the ability of currently available assays to address this
- The opportunity to improve translation via the use of biomarkers
- Data sets required by industry partners, VCs, PIs and regulators

**Emily Offer**
Principal Scientist and Team Leader
**Redx Immunology**

**13.10 Case Study: Selective ROCK-2 Inhibitor Programme**
- ROCK2 as a kinase central to the signalling processes involved in aberrant wound healing and fibrosis.
- Up-regulation in acute and chronic inflammation
- Inhibition of ROCK2 reduces the pro-fibrotic and pro-inflammatory response disease relevant in vitro and in vivo models

**13.30 Q&A Panel: Novel Targets, Molecules and Pathways**

**13.45 Lunch Seminar**
Maximize productivity by pairing food with food-for-thought at the optional lunchtime seminar.

**13.45 Lunch Networking Break**

## Preclinical Sessions: Translating Biology from Animal to Patient

**John Atkinson**
Senior Research Scientist Tissue Remodelling
**UCB**

**14.45 Case Study: Successful Clinical Trials Start with Carefully Curated Animal Models**
- Specify readouts based on the biology of the target to reflect the chosen mechanism of action
- Adopt a poly-pharmacy approach for increased effectiveness
- Move away from inbred strains in animal models and diversify environment and age ranges

**Lee Borthwick**
Fibrosis Biology Lecturer and Chief Operating Officer FibroFind
**Newcastle University**

**15.05 Case Study: Next Generation *In Vitro* Models**

- Ensure a smoother transition to clinical trial with precision cut slice technology that mimics the function of the organ
- Recreate the organ culture by replicating the biology and cells that would be found in a person
- Stimulate the culture with a cause relevant to the chosen clinical disease for authentic progression of fibrosis
- Use of precision cut slices for the modelling of fibrosis

**15.25 Afternoon Networking Break**

## Preclinical Sessions: Translating Biology from Animal to Patient

**Scott Macdonnell**
Senior Staff Scientist
**Regeneron**

**15.55 Case Study: Defining "Activated" Fibroblasts using Single Cell Sequencing**

- Understand the characteristics of the underlying fibroblast cell population beyond the current recognition as the central mediators of extra-cellar matrix deposition in IPF
- Use of an unbiased single cell RNA-sequencing analysis of a bleomycin-induced pulmonary fibrosis model to characterize molecular responses to fibrotic injury at the single cell level
- Analysis of gene expression as analyzed by 3 complementary techniques which together generated a 49-gene signature that defined an activated subpopulation of fibroblasts

**Komathi Stem**
Chief Executive Officer
**MonArc Bionetworks**

**16.15 Case Study: Develop Patient Relationships at the Preclinical Stage to Identify the Best Patient Population for your Treatment**

- Generate evidence for clinical trial stage from early-on to make the transitional period seamless and ensure success
- Application of RWE in IPF clinical trials – translating success from the real world and fibrotic patient experience
- Identify patients despite low diagnosis rate by correlating data and maintaining a registry with specific disease indicators

**Tim Johnson**
Director Immunology Therapeutic Area
**UCB**

**16.30 Case Study: Use of Technology in the Development of TG2 Inhibitory Therapeutics**

- Development of a glomerular sclerosis organoid model
- Responses in organoid models which recapitulate rodent *in vivo* data
- Creation of CKD primate models for antibody therapies
- Use of surrogate biomarkers for *in vivo* studies

**16.50 Q&A Panel: Translating Biology from Animal to Patient**

**17.10 Speed Learning**

**Roundtable discussions like you've never seen them before.**
Uncover the story behind four fibrotic therapeutic developments in one quick-fire session. Each table will be hosted by leading specialist who will share the secrets of their most high-impact strategy; you then get the opportunity to question the host before moving on to your next table.

**18.10 Poster Session and Drinks Reception**

Constructive conversations over cocktails and canapés to the backdrop of posters.

"The only meeting to attend if you want to learn about state of the art developments in fibrosis"
Vincenza di Modugno, Director, Roche

# Conference Day Two
# Wednesday November 20 2019

**8.00 Welcome Coffee**

**Alexey Lugovskoy**
Chief Development Officer
**Morphic Therapeutics**

**8.20 Chair's Opening Remarks**

## Spotlight on Fibrotic Disease Areas

**Jean-Francois Thibodeau**
Research Scientist
**Prometic Biosciences**

**8.30 Case Study: Novel Compounds to Target Alstrom**

- Develop a drug that works through binding activation and inhibition of receptors found in macrophages and immune cells
- Target the initial inflammatory process to prevent the progression of fibrotic disease

**Sten R. Sörensen**
Chief Executive Officer
**Cereno Scientific**

**Bertram Pitt**
Professor of Medicine Emeritus
**University of Michigan School of Medicine**

**8.50 Fireside Chat: Advancements in Cardiovascular Fibrosis**

- Discover new therapeutic targets outside of diabetes and blood-pressure which contribute to cardiovascular disease
- Detect myocardial fibrosis with collagen and IL11 biomarkers
- Selective small molecule inhibitors within cardiac fibrosis

**9.10 Panel: Advancements in Metabolic Fibrosis**

- Combination therapies for NASH and Chronic Kidney Disease
- The relationship between diabetes and CKD – can common therapies be effectively used to treat both conditions?
- Tissue targeting in CKD – increasing efficacy, reducing toxicity
- Novel molecular targets including Galectin-3 inhibitors and HSP47

**Moderator:**

**Matthew Breyer**
Distinguished Scientist CVM
**Janssen**

**Panellists:**

**Min Lu**
Morphic Therapeutics
**Head of Fibrosis**

**Tim Johnson**
Director Immunology Therapeutic Area
**UCB**

**Lisa Hazelwood**
Principal Scientist Liver Disease and Fibrosis Discovery
**Abbvie**

**Resat Cinar**
Staff Scientist
**National Institute on Alcohol Abuse and Alcoholism**

**9.50 Panel: Advancements in Pulmonary Fibrosis**

- The relationship between Pulmonary Arterial Hypertension and IPF – common mechanisms to target and combination therapies
- The transference of inhalant technology from COPD to IPF
- Small molecule therapies that target novel mechanisms

**Moderator:**

**Scott Macdonnell**
Senior Staff Scientist
**Regeneron**

**Panellists:**

**Kirby von Kessler**
Associate Director Clinical Development
**Lung Biotechnology**

**Rozsa Schlenker - Herceg**
Executive Director Clinical Research, Medical Affairs and Respiratory
**Boehringer-Ingelheim**

**Weilin Xie**
Senior Principal Scientist
**Celgene Corporation**

**Rick Keenan**
Chief Scientific Officer
**OptiKira**

**Moustapha El-Amine**
Director Global Search and Evaluate
**AstraZeneca**

**10.30 Morning Networking Break**

## Spotlight on the Relationship between Fibrosis and Cancer

**Gilles Tremblay**
Director Preclinical Development
**Forbius**

**11.00 Case Study: Novel Inhibitors of TGF Beta for Fibrotic Cancer**

- Tackle the barrier created by fibroblasts in the tumour microenvironment which prevents immune cells from targeting cancerous cells
- Understand the role of TGF Beta within fibrotic cancers and create a novel inhibitor of TGF Beta Ligands
- Consider the role of stromal components and the secretion of cytokines within cancer fibroblast to find a combined immune checkpoint and TGF Beta inhibitors treatment

**11.20 Panel: You Can't Teach an Old Pathway New Tricks; the Case for and Against TGF Beta as a Primary Target for Fibrosis and Fibrotic Cancers**

- Can inhibiting TGF Beta alone stop the progression of fibrosis?
- Does the reduction of TGF Beta in animal models result in strong histological end points at clinical trial?
- Is there a common TGF Beta pathway to target which will attack fibrotic cancers?

**Moderator:**

**Gilles Tremblay**
Director Preclinical Development
**Forbius**

**Panellists:**

**Ravi Kumar**
Senior Vice President and Chief Scientific Officer
**Acceleron Pharma**

**Zoe Johnson**
Chief Scientific Officer
**iOnctura**

**Gail Walkinshaw**
Vice President Research
**FibroGen**

## Clinical Sessions: Overcoming Failures

**Gail Walkinshaw**
Vice President Research
**FibroGen**

**12.00 Tactics to move a clinical trial to phase III with minimal risk of failure**

- Understand the main causes of AFDD clinical trial failures and discover solutions that prevent future breakdowns
- Clinical trial design which is failure-proof
- Learn to pre-empt and adapt in the face of problems to ensure success

**Robert Edwards**
Director and CVM Clinical Project Specialist
**Janssen**

**12.20 A Blueprint for Success: J&J's CREDENCE Clinical Trial**

- Patient recruitment: a global multidisciplinary effort required perseverance
- Adjudication: a concerted cross-functional effort required diligence and determination
- Patient retention: a top priority from Day 1 left no stone unturned

**12.40 Q&A Panel: Overcoming Clinical Trial Failures**

**13.00 Lunch Break**

**14.00 Wrap Up Roundtables**

**10 tables, 10 problems, 10 solutions. Ready, set, resolve!**

- Select a pathway outside of TGF Beta to target in the treatment of fibrosis – define the drug development plan for this pathway
- Inhibitors vs inducers: create a plan to develop either an inhibiting or inducing anti-fibrotic treatment. Explain why you selected the inhibitor/ inducer.
- Design a novel biomarker and explain its application to both the preclinical and clinical stage
- Define a common mechanism to target in order to create an anti-fibrotic drug which will treat all fibrotic disease areas
- Design a preclinical plan with animal models that will effectively translate to the clinic
- Design a preclinical plan with only in vitro models
- Incorporate the use of technology into the development of an anti-fibrotic drug
- Develop a treatment for a patient with fibrotic cancer
- Translate J&J's CREDENCE trial into a clinical trial design for an anti-fibrotic treatment
- Design a patient recruitment programme for an anti-fibrotic clinical trial

## Look to the Future: Academic Showcase

**Aftab Taiyab**
Research Scientist
**McMaster University**

**15.00 Ocular Fibrosis: See Common Mechanisms in a New Light**

- The non-canonical signalling pathway indicative of ocular fibrosis which is also found in IPF and renal
- Targeting the transformation to myofibroblasts, from epithelial to mesenchymal cells
- Learnings from ocular fibrosis mechanisms that share commonalities with other fibrotic conditions and discovery of shared biomarkers

**Yaron Ilan**
Director Department of Medicine
**Hebrew University Hadassah Medical Center**

**15.20 The Gut as a Target for Anti-Fibrotic Therapy in NASH**

- Using the gut for systemic immune modulation without immune suppression
- Generating an immune signal in the gut for re-directing the immune system in an anti-inflammatory way
- Targeting the gut microbiome for alleviation of fibrosis

**15.40 Panel: Spotlight on Scleroderma**

- *In vitro* skin based assays and how they can be applied to other conditions
- Genetic skin models including rare disease RDEB
- Blood test biomarkers indicative of scleroderma

**Shervin Assassi**
Professor of Medicine and Co-Director of the UTHealth Scleroderma Program
**University of Texas Health Science Center at Houston**

**Robert Lafyatis**
Adjunct Professor Medicine
**Boston University**

**Anie Philip**
Professor Department of Surgery
**Research Institute of the McGill University Health Center**

**Alexey Lugovskoy**
Chief Development Officer
**Morphic Therapeutics**

**16.20 Chair's Closing Remarks**

**16.30 Networking Coffee to Stay or Go**

# Event Themes:

Gain insights into the latest **novel molecules and pathways** to identify the **best fibrotic mechanism** to target

Explore opportunities for **combination therapies** in **fibrosis** and **oncology**

Ensure **successful translation** from *in vivo* and *in vitro* models to clinical trial through the consistent application of **biomarkers** and **clinical endpoints**

# Maximize your ROI at the only conference to bring together industry and leaders across fibrotic disciplines

## Spotlight Partner:

monARC Bionetworks is a healthcare technology company on a mission to modernize the clinical research industry by empowering patients to share their data and participate anytime, anywhere. By allowing patients to directly donate their data, monARC is creating a new data-sharing economy that will transform the highly sequential and siloed drug development model into an integrated and a collaborative model with patients.

**www.monarcbio.com**

## Spotlight Partner:

The development of better medicine begins with better disease models. Unfortunately, current in vitro models poorly mimic the pathophysiology of fibrosis, leaving a major gap in compound screening and testing efforts in anti-fibrosis drug discovery. Xylyx Bio's native, disease-specific extracellular matrix substrates allow drug candidates to be investigated in vitro in a disease-relevant environment, enabling cell models that are significantly more predictive of human pathophysiology. Xylyx Bio products comprise both the mechanical properties and complex ratios of ECM components specific and unique to each organ type and disease state and are available in a variety of 2D and 3D product formats to support high-throughput assays

**www.xylyxbio.com**

## Spotlight Partner:

TherapeutAix is a life sciences consultancy company based in Aachen, Germany, combining drug discovery and development expertise with a fully integrated R&D network, to deliver practical, cost and time effective solutions to drug discovery projects. It supports investors and project teams focus on the next step, progress the right assets through robust decision-making steps, with a clear line of sight to the next value-inflection point and the clinic. Since its formation in 2018, TherapeutAix has successfully conducted project reviews, developed strategies and operationalised programs for biotech, pharma and investors in fibrosis, NASH and other therapeutic areas

**www.therapeutaix.com**

## Exhibition Partner:

Biomodels LLC, a preclinical CRO, conducts predictive and translational studies for biotechnology and pharmaceutical companies in the areas of fibrosis, pulmonary and inflammatory diseases, in addition to several other clinical indications. Biomodels specializes in (non-GLP) customized efficacy studies that optimize dose, schedule, and define mechanism of action. Additionally, Biomodels' state of the art Germ-Free and Gnotobiotic animal facility allows for the analysis of the role of the microbiota both in disease pathogenesis and in therapeutic efficacy.

**www.biomodels.com**

## Why the AFDD Summit?

The **3rd AFDD Summit** is the fastest route to in-depth discussions with organizations prioritizing anti-fibrotic drug development. AFDD provides an unrivaled opportunity for your brand, your message and your reputation to be showcased in front of the leading minds of the growing 'Fibrosis Industry'.

## Who do I get to meet?

Gathering stakeholders and key opinion leaders, the AFDD Summit is the ultimate opportunity to position yourself as an expert in front of 100+ drug developers. Elevate your company's standing and influence the future of anti-fibrotic drug development.

## What can the AFDD Summit do for you?

**Boost** your brand; **engage** industry decision makers; **demonstrate** thought leadership

We understand each business is different so we'll work with you to build a bespoke partnership opportunity to fulfill your 2019/2020 business objectives.

## How is AFDD different?

At this year's Anti-Fibrotic Drug Development Summit, you can expect:

**A HIGHER CALIBER OF CONVERSATIONS:** with over 10 hours of networking you'll have more opportunities than ever for significant discussions with your key prospects

**DEDICATED ICEBREAKER SESSIONS FROM THE START:** starting a conversation is never easy, so let us start them for you

**INTERACTIVE SESSIONS AS STANDARD:** engage your audience in solution-focused exchanges at this year's panel discussions, speed learning roundtables and poster session

# Get Involved

**Jakub Nunuk**
Partnership Manager
Tel: +1617 455 4188
Email: sponsor@hansonwade.com

# Ready to Register?

**Jack Bainbridge**
Delegate Experience Manager
Tel: +1 617 455 4188
Email: info@hansonwade.com

## 3 Easy Ways To Book

www.afdd-summit.com/take-part/register/

Tel: +1 617 455 4188

Email: register@hansonwade.com

## Team Discounts*

- **20% discount – 4+ delegates**
- **15% discount – 3 delegates**
- **10% discount – 2 delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.
Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.
Contact: register@hansonwade.com

## SECURE YOUR PLACE

| Industry Pricing | Register & Pay By Friday, August 23 | Standard Rate |
|---|---|---|
| **Full Access: Conference + Workshop Day** (A in AM) **&** (B or C in PM) | $3697 **(save $600)** | $3997 **(save $300)** |
| **Conference Only** | $2499 **(save $400)** | $2899 |
| **Workshop Day Only** (A in AM) **&** (B or C in PM) | $1299 | |

*workshops can be purchased individually contact info@hansonwade.com
** Start up and academics are entitled to 40% discount off the industry price.
*** Past attendees (NASH, CKD3 and IPF) and event speakers are entitled to 10% discount off the industry price.



## VENUE

**The Revere Boston Common**
200 Stuart St, Boston, MA 02116, USA
**For further information or assistance, please visit www.reverehotel.com**



Code: 12561